Diascan AB has a 25 year long background in computer assisted cytology/pathology. Thecompany was founded in May 1988 to become the home of the Diascanner PAP-smear screening system which was under development in Uppsala. Eventually a handful of such screening devices were built and initial field tests were carried out with promising results. However, the systems turned out not to be cost effective, the technology was not sufficiently mature yet. So the Diascanner project was discontinued.

 

During the first half of the 90's Diascan developed a software tool for Quantiative Pathological Diagnostics, QPD, in collaboration with Wallac OY in Finland, then owned by Pharmacia, and with support from Vinnova. Wallac got new american owners who decided to close down the project, however Diascan was able to retain the IP for the software. Diascan sold the software to a few customers but no sustainable market presence was established.

 

In the late 90's and the first decades of this millennium Diascan carried out a few small consulting task and became holding company for a patent in quantitative microscopy. The company also became involved in a collaboration with CDAC, the Centre for Advanced Computing, in Thiruvananthapuram, India, with the goal of developing a cervical cancer screening system initially for the Indian market but potentially world-wide. The project is still active but Diascan is no longer directly involved. In 2020 Diascan became involved in a project in AI based prostate pathology grading. It lead to the formation of a new company Spearpoint Analytics AB where Diascan is a minority owner. Also the shareholder base of Diascan was increased with two new owners.